Resumen
Pancreatic ductal adenocarcinoma (PDAC) continues to be a significant challenge in cancer management, with predictions indicating it will become the second leading cause of cancer-related death by 2030. The persistent poor outcomes in PDAC are partly attributed to a complex tumor microenvironment (TME) that inhibits anti-tumor immunity, restricts the penetration of therapeutics, and facilitates cancer dissemination. Only a few aspects of the TME are routinely documented in the clinical setting, but this may evolve as new TME-directed therapies are developed. In this review, we cover relevant aspects of modern PDAC management, summarize TME-related biomarkers and clinical trials, and discuss the potential challenges associated with evaluating the TME in a clinical context.